Abbott Laboratories vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 79)
Abbott Laboratories logo

Abbott Laboratories

LeaderHealthcare

General

Diversified healthcare company with $20-22B revenue; FreeStyle Libre CGM, cardiovascular devices, and diagnostics across medical devices, nutrition, and pharma.

AI VisibilityBeta
Overall Score
B79
Category Rank
#29 of 596
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
74
Perplexity
84
Gemini
74

About

Abbott Laboratories is a diversified global healthcare company operating across diagnostics, medical devices, nutritional products, and established pharmaceuticals in over 160 countries. Founded in 1888 by Dr. Wallace Calvin Abbott in Chicago, Illinois and listed on the NYSE, Abbott generates approximately $20-22 billion in annual revenue and employs over 100,000 people globally. The company's portfolio spans four major segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

79
Overall Score
90
#29
Category Rank
#2
73
AI Consensus
83
stable
Trend
stable
74
ChatGPT
92
84
Perplexity
93
74
Gemini
89
81
Claude
96
80
Grok
95

Key Details

Category
General
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.